FBIO Earnings Date: Nov 16, 2026 (Estimated) — Fortress Biotech, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is FBIO's next earnings date?
Fortress Biotech, Inc. (FBIO) is expected to report earnings on Monday, November 16, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.27 on revenue of $21.6M.
How did FBIO do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), Fortress Biotech, Inc. posted EPS of -$0.08 versus the -$0.20 estimate, a beat of 60.0%. Revenue was $18.7M against a $18.3M estimate. The stock's 1-day post-earnings move was -1.7%.
How much does FBIO stock move after earnings?
FBIO beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.3% (up or down) in the day after earnings.
About Fortress Biotech, Inc.
Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases). Other products in this segment are Exelderm cream for fungal skin infections like ringworm and jock itch, Ceracade for dry skin conditions, Luxamend for wound care, and Accutane capsules for particularly severe, stubborn nodular acne. Its pipeline features several promising late-stage drug candidates, targeting a diverse range of medical needs. These include intravenous Tramadol for acute post-operative pain, CUTX-101 (an injection for Menkes disease), MB-107 and MB-207 for X-linked severe combined immunodeficiency, Cosibelimab for metastatic cancers, CK-101 for non-small cell lung cancer characterized by EGFR mutations, CAEL-101 for amyloid light chain (AL) amyloidosis, the Triplex vaccine for cytomegalovirus, and CEVA101 for critical traumatic brain injuries in adults and children. Furthermore, its earlier-stage research encompasses various investigational treatments such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, MB-101 for glioblastoma, MB-104 for multiple myeloma and light chain amyloidosis, MB-106 for B-cell non-Hodgkin lymphoma, MB-103 for glioblastoma and metastatic breast cancer to the brain, MB-108, MB-105 for prostate and pancreatic malignancies, and BAER-101. In the preclinical phase, Fortress Biotech is exploring an array of novel therapeutic approaches. These comprise AAV-ATP7A and AVTS-001 (both gene-based therapies), the CK-103 BET inhibitor, CEVA-D and CEVA-102, CK-302 (an antibody targeting GITR), CK-303 (an antibody against CAIX), ConVax, and the ONCOlogues oligonucleotide platform. The company also actively engages in collaborative ventures with universities, research institutions, and other pharmaceutical organizations. Originally established in 2006, the entity operated as Coronado Biosciences, Inc. before rebranding as Fortress Biotech, Inc. in April 2015. Its corporate headquarters are situated in Bay Harbor Island, New York.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.20 | -0.08 | +60.00% | $18.7M | ✅ Beat | -1.68% | -7.05% | -15.10% |
| 2026-05-14 | Q1 2026 | -0.08 | 2.82 | +3625.00% | $16.0M | ✅ Beat | +4.78% | +20.87% | +24.35% |
| 2026-03-31 | Q4 2025 | 0.23 | -0.30 | -230.43% | $16.1M | ❌ Miss | -11.47% | -17.20% | -17.56% |
| 2025-11-14 | Q3 2025 | -0.55 | 0.11 | +120.00% | $17.6M | ✅ Beat | +5.22% | +1.61% | +33.33% |
| 2025-08-14 | Q2 2025 | -0.31 | -0.46 | -48.39% | $16.4M | ❌ Miss | +8.16% | +14.29% | +81.12% |
| 2025-03-31 | Q4 2024 | -0.75 | -0.26 | +65.33% | $15.1M | ✅ Beat | -1.28% | -5.77% | +13.46% |
| 2024-11-14 | Q3 2024 | -0.59 | -0.76 | -28.81% | $14.6M | ❌ Miss | -8.92% | +0.00% | +17.83% |
| 2024-08-13 | Q2 2024 | -1.23 | -0.73 | +40.65% | $14.9M | ✅ Beat | -1.09% | +6.56% | +0.00% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $8.5M total
| Segment | Share | Revenue | YoY | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 |
|---|---|---|---|---|---|---|---|
| Qbrexza | 60.4% | $5.1M | -26.4% | $5.0M | $6.8M | $7.6M | $13.3M |
| Accutane | 39.6% | $3.4M | -1.1% | $5.8M | $5.7M | $4.0M | $7.9M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.